We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Alok Khorana

Alok A Khorana MD, FACP, FASCO

Alok A. Khorana is Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, the Sondra and Stephen Hardis Chair in Oncology Research, Vice-Chair for Clinical Services of the Taussig Cancer Institute (part of Case Comprehensive Cancer Center) and Director of the Gastrointestinal Malignancies Program at the Cleveland Clinic, Cleveland, Ohio. His clinical and translational research program focuses on predictive factors and drug development in cancer-associated thrombosis and gastrointestinal cancers and has been funded by grants from the National Cancer Institute, the National Heart, Lung, and Blood Institute, the Hardis Family, the Porter Family Fund, VeloSano, the Scott Hamilton CARES Initiative, Stand Up To Cancer (Colorectal Cancer “Dream Team”) and the V Foundation. 

Dr. Khorana received his medical degree from Maharaja Sayajirao University’s Medical College in Baroda (now Vadodara, Gujarat), India. His postdoctoral training included a residency in internal medicine at the University at Buffalo in New York and a fellowship in hematology/oncology at the University of Rochester, New York. He is a Fellow of the American College of Physicians and in 2018 was elected Fellow of the American Society of Clinical Oncology.

Disclosures

Dr. Khorana reports the following disclosures: personal fees from Janssen, Bayer, sanofi, Pfizer, Leo Pharma, Halozyme, AngioDynamics, Pharmacyte, Incyte, Trisalus and research funding to institution from Bristol Myers and Merck.

 

Recent Contributions to PracticeUpdate:

  1. Apixaban to Prevent VTE in Patients With Cancer